A Phase 1/2 interventional study of Lenvatinib and Pembrolizumab in Tumors, sponsored by Eisai Inc.. Completed at 64 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-20.
Sponsored by Eisai Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous [IV], every 3 weeks [Q3W]) pembrolizumab in participants with selected solid tumors (i.e. non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, melanoma or leiomyosarcoma). Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 7 cohorts at the MTD from Phase 1b (lenvatinib 20 mg/day orally + pembrolizumab 200 mg Q3W, IV).
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 357 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase 1b: and/or cytologically confirmed selected solid tumor types that have progressed after treatment with approved therapies or for which there are no standard effective therapies available. If nivolumab or pembrolizumab is an approved therapy for the participant's tumor type, but the participant has not been treated with it, the Investigator may enroll the participant in this study.
Phase 2: Histologically and/or cytologically confirmed metastatic selected solid tumor types with 0-2 . If previously treated, participant has progressed after previous treatment. For the non-small cell lung cancer (NSCLC) and melanoma cohorts, participants must have progressed on or after prior treatment with one anti-programmed cell death protein 1 (), anti-PD-1 ligand 1 (anti-PD-L1), or anti-PD-1 ligand 2 (anti-PD-L2) agent. For the renal cell carcinoma (RCC) cohort, participants must have progressed on treatment with an anti- programmed death receptor-1 /programmed death receptor-ligand 1 monoclonal antibody (anti-PD-1/PD-L1 mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies, the regimen with an anti-PD-1/PD-L1 mAb must be the most recent therapy. Selected tumor types of both phases: NSCLC, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma (excluding uveal melanoma)
Phase 2: meeting the following criteria:
Adequate bone marrow function:
All females must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotropin [β-hCG]) at the Screening Visit and the Baseline Visit. A pregnancy test needs to be performed within 72 hours of the first dose of study drug. Females of must agree to use a highly effective method of for the entire study period and for 120 days after study discontinuation, ie
NOTES:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with one of the tumors: non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, squamous cell carcinoma of the head and neck, melanoma or leiomyosarcoma.
Drug: Lenvatinib · Drug: Pembrolizumab
Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
Also known as: Lenvima, E7080
Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
Also known as: Keytruda, MK-3475
Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib
MTD was confirmed if no more than 3 participants experience dose-limiting toxicities(DLTs)during first 3 weeks (Cycle 1) of treatment.If MTD was not confirmed at dose level,then enrollment was proceeded to next lower dose level.Sponsor and investigators reviewed all participants' safety;clinical data to jointly determine RP2D of combination of treatment.DLT may be any of following: hematological/nonhematological toxicities considered to be at least possibly related to Lenvatinib/pembrolizumab occurring during Cycle 1;Failure to administer greater than or equal to (\>=) 75 percent (%) of planned dosage of lenvatinib as result of treatment-related toxicity during Cycle 1;Who discontinue treatment due to treatment-related toxicity.Greater than 2 week delay in starting Cycle 2 because of treatment-related toxicity,even if toxicity does not meet DLT criteria.Toxicity was evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03(NCI CTCAE v 4.03).
Time frame: Cycle 1 (21 days)
Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) of Lenvatinib
A DLT was defined as any of the following: any of the hematological or nonhematological toxicities considered to be at least possibly related to lenvatinib and/or pembrolizumab occurring during Cycle 1. Failure to administer \>=75% of the planned dosage of lenvatinib as a result of treatment-related toxicity during Cycle 1. Participants who discontinue treatment due to treatment-related toxicity. Greater than 2 week delay in starting Cycle 2 because of a treatment-related toxicity, even if the toxicity does not meet DLT criteria. Toxicity was evaluated as per NCI CTCAE v 4.03.
Time frame: Cycle 1 (21 days)
Objective Response Rate (ORR) Based on Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) Version 1.1 at Week 24
ORR was defined as the percentage of participants whose best overall response (BOR) was immune related complete response (irCR) or immune related partial response (irPR) based on investigator assessment according to irRECIST version 1.1. irCR was defined as disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (\<) 10 millimeter (mm). irPR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
TEAE: adverse event (AE) emerged during treatment, having been absent at pretreatment or reemerged during treatment, present at pretreatment but stopped before treatment or worsened in severity during treatment relative to pretreatment state, when AE is continuous. AE: any untoward medical occurrence in participant administered an investigational product. TEAEs were based on participants laboratory tests, regular measurement of vital signs, echocardiograms/multigated acquisition scans to assess left ventricular ejection fraction and electrocardiograms parameter values. TESAE: any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; a congenital anomaly/birth defect or was medically important due to reasons other than above criteria.
Time frame: From date of first dose up to 30 days after the last dose of study drugs (Up to 74 months)
Objective Response Rate (ORR) Based on irRECIST Version 1.1
ORR was defined as the percentage of participants whose BOR was irCR or irPR according to irRECIST version 1.1. irCR was defined as disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to \<10 mm. irPR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: From date of first dose of study drug administration until immune related (irPD), development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)
Progression-free Survival (PFS) Based on irRECIST Version 1.1
PFS was defined as the time from the first dose date to the date of irPD or date of death (whichever occurred first) according to irRECIST version 1.1. irPD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions was also considered progression).
Time frame: From date of first dose of study drug administration to date of irPD or date of death, whichever occurred first (up to 73 months)
Overall Survival (OS)
OS was defined as the time from the first dose date to the date of death from any cause.
Time frame: From the first dose until death from any cause, up to 73 months
Disease Control Rate (DCR) Based on irRECIST Version 1.1
DCR: percentage of participants with a confirmed irCR, irPR, or ir-stable disease (SD) (duration of irSD greater than or equal to \[\>=\] 5 weeks). DCR was assessed on irRECIST v1.1. irCR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in their short axis to \<10 mm. irPR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference baseline sum of longest diameter. irSD: neither sufficient shrinkage to qualify for irPR nor sufficient increase to qualify for irPD, taking as reference smallest sum diameters while on study. irPD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).
Time frame: From first dose of the study drug until irPD, development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)
Clinical Benefit Rate (CBR) Based on irRECIST Version 1.1
CBR was defined as the percentage of participants with BOR of irCR or irPR or irdurable stable disease (irdSD) (duration of irSD \>=23 weeks) \[irCR + irPR + irdSD\] based on irRECIST v1.1. irCR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in their short axis to \<10 mm. irPR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference baseline sum of longest diameter. irSD: neither sufficient shrinkage to qualify for irPR nor sufficient increase to qualify for irPD, taking as reference smallest sum diameters while on study. irPD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).
Time frame: From first dose date until irPD, development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)
Durable Stable Disease Rate (DSDR) Based on irRECIST Version 1.1
Durable SD rate is defined as the percentage of participants whose observed BOR is irSD and the duration of irSD is \>=23 weeks based on irRECIST v1.1.
Time frame: From first dose date until irPD, development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)
Duration of Objective Response (DOR) Based on irRECIST Version 1.1
DOR: time from date of first observation of response (irPR or irCR) to date of the first observation of progression based on irRECIST 1.1, or date of death, whatever the cause. irCR: disappearance of all target and non-target lesions. All pathological (whether target or non-target) must have reduction in their short axis \<10 mm. irPR: at least 30% decrease in sum of diameter (SOD) of target lesions, taking as reference baseline sum diameters. irPD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in SOD of target lesions, taking as reference smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: First documentation of irCR or irPR until first documentation of progression or death (up to 73 months)
Phase 1b: Plasma Concentrations of Lenvatinib
Observed plasma concentration of Lenvatinib was reported here quantified by liquid chromatography with tandem mass spectrometry (LCMS/MS) method.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post dose; Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours post dose, Cycle 2 Day 1: predose, 2-12 hour postdose and Cycles 3,4,5,6 Day 1 predose (Cycle length =21 days)
Plasma Concentrations of Lenvatinib
Observed plasma concentration of Lenvatinib was reported here quantified by LCMS/MS method.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post dose; Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours post dose, Cycle 2 Day 1: predose, 2-12 hour postdose and Cycles 3,4,5,6 Day 1 predose (Cycle length =21 days):
Participants took part in the study at 62 investigative sites in the United States, Spain and Norway from 22 July 2015 to 11 July 2022.
| Milestone | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma |
|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 124 | 145 | 21 | 21 | 22 | 20 | 1 |
| Phase 1b participants who received, lenvatinib 20 mg/day + pembrolizumab 200 mg. | 0 | 0 | 2 | 6 | 1 | 1 | 0 | 0 | 0 |
| Phase 2 participants who received, lenvatinib 20 mg/day + pembrolizumab 200 mg | 0 | 0 | 122 | 139 | 20 | 20 | 22 | 20 | 1 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 1 | 124 | 145 | 21 | 21 | 22 | 20 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 7 | 13 | 2 | 2 | 2 | 3 | 0 |
| Withdrew: Survival follow-up discontinued by sponsor | 0 | 0 | 29 | 58 | 3 | 2 | 2 | 1 | 0 |
| Withdrew: Death | 1 | 1 | 88 | 74 | 15 | 16 | 15 | 16 | 1 |
MTD was confirmed if no more than 3 participants experience dose-limiting toxicities(DLTs)during first 3 weeks (Cycle 1) of treatment.If MTD was not confirmed at dose level,then enrollment was proceeded to next lower dose level.Sponsor and investigators reviewed all participants' safety;clinical data to jointly determine RP2D of combination of treatment.DLT may be any of following: hematological/nonhematological toxicities considered to be at least possibly related to Lenvatinib/pembrolizumab occurring during Cycle 1;Failure to administer greater than or equal to (\>=) 75 percent (%) of planned dosage of lenvatinib as result of treatment-related toxicity during Cycle 1;Who discontinue treatment due to treatment-related toxicity.Greater than 2 week delay in starting Cycle 2 because of treatment-related toxicity,even if toxicity does not meet DLT criteria.Toxicity was evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03(NCI CTCAE v 4.03).
| milligram (mg) | Phase 1b: All Participants |
|---|---|
| MTD | 20 |
| RP2D | 20 |
A DLT was defined as any of the following: any of the hematological or nonhematological toxicities considered to be at least possibly related to lenvatinib and/or pembrolizumab occurring during Cycle 1. Failure to administer \>=75% of the planned dosage of lenvatinib as a result of treatment-related toxicity during Cycle 1. Participants who discontinue treatment due to treatment-related toxicity. Greater than 2 week delay in starting Cycle 2 because of a treatment-related toxicity, even if the toxicity does not meet DLT criteria. Toxicity was evaluated as per NCI CTCAE v 4.03.
| Participants | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC | Phase 1b, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg: NSCLC | Phase 1b, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg: RCC | Phase 1b, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg: EC | Phase 1b, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg: Melanoma |
|---|---|---|---|---|---|---|
| Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) of Lenvatinib | 1 | 1 | 0 | 0 | 0 | 0 |
ORR was defined as the percentage of participants whose best overall response (BOR) was immune related complete response (irCR) or immune related partial response (irPR) based on investigator assessment according to irRECIST version 1.1. irCR was defined as disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (\<) 10 millimeter (mm). irPR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters.
| percentage of participants | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma |
|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) Based on Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) Version 1.1 at Week 24 | 39.5 (30.9 to 48.7) | 56.6 (48.1 to 64.8) | 47.6 (25.7 to 70.2) | 23.8 (8.2 to 47.2) | 31.8 (13.9 to 54.9) | 25.0 (8.7 to 49.1) | 0 (NA to NA) |
TEAE: adverse event (AE) emerged during treatment, having been absent at pretreatment or reemerged during treatment, present at pretreatment but stopped before treatment or worsened in severity during treatment relative to pretreatment state, when AE is continuous. AE: any untoward medical occurrence in participant administered an investigational product. TEAEs were based on participants laboratory tests, regular measurement of vital signs, echocardiograms/multigated acquisition scans to assess left ventricular ejection fraction and electrocardiograms parameter values. TESAE: any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; a congenital anomaly/birth defect or was medically important due to reasons other than above criteria.
| Participants | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma |
|---|---|---|---|---|---|---|---|---|---|
| TEAEs | 2 | 1 | 124 | 145 | 21 | 21 | 22 | 20 | 1 |
| TESAEs | 1 | 1 | 73 | 81 | 12 | 15 | 12 | 17 | 0 |
ORR was defined as the percentage of participants whose BOR was irCR or irPR according to irRECIST version 1.1. irCR was defined as disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to \<10 mm. irPR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters.
| percentage of participants | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma |
|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) Based on irRECIST Version 1.1 | 40.3 (31.6 to 49.5) | 63.4 (55.1 to 71.3) | 47.6 (25.7 to 70.2) | 23.8 (8.2 to 47.2) | 40.9 (20.7 to 63.6) | 25.0 (8.7 to 49.1) | NA (NA to NA) |
PFS was defined as the time from the first dose date to the date of irPD or date of death (whichever occurred first) according to irRECIST version 1.1. irPD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions was also considered progression).
| months | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma |
|---|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) Based on irRECIST Version 1.1 | 7.5 (5.3 to 9.7) | 14.1 (11.6 to 18.4) | 5.5 (2.6 to 15.8) | 5.4 (2.3 to 7.4) | 4.4 (4.0 to 9.8) | 5.4 (1.3 to 42.3) | 1.35 (NA to NA) |
OS was defined as the time from the first dose date to the date of death from any cause.
| months | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma |
|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 19.9 (16.2 to 25.9) | 32.2 (29.8 to 55.8) | 25.4 (8.6 to 39.5) | 11.4 (3.6 to 23.3) | 16.2 (8.6 to 31.8) | 6.1 (2.4 to 30.1) | 16.56 (NA to NA) |
DCR: percentage of participants with a confirmed irCR, irPR, or ir-stable disease (SD) (duration of irSD greater than or equal to \[\>=\] 5 weeks). DCR was assessed on irRECIST v1.1. irCR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in their short axis to \<10 mm. irPR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference baseline sum of longest diameter. irSD: neither sufficient shrinkage to qualify for irPR nor sufficient increase to qualify for irPD, taking as reference smallest sum diameters while on study. irPD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).
| percentage of participants | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma |
|---|---|---|---|---|---|---|---|
| Disease Control Rate (DCR) Based on irRECIST Version 1.1 | 84.7 (77.1 to 90.5) | 93.8 (88.5 to 97.1) | 81.0 (58.1 to 94.6) | 76.2 (52.8 to 91.8) | 90.9 (70.8 to 98.9) | 70.0 (45.7 to 88.1) | NA (NA to NA) |
CBR was defined as the percentage of participants with BOR of irCR or irPR or irdurable stable disease (irdSD) (duration of irSD \>=23 weeks) \[irCR + irPR + irdSD\] based on irRECIST v1.1. irCR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in their short axis to \<10 mm. irPR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference baseline sum of longest diameter. irSD: neither sufficient shrinkage to qualify for irPR nor sufficient increase to qualify for irPD, taking as reference smallest sum diameters while on study. irPD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).
| percentage of participants | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma |
|---|---|---|---|---|---|---|---|
| Clinical Benefit Rate (CBR) Based on irRECIST Version 1.1 | 58.9 (49.7 to 67.6) | 80.0 (72.6 to 86.2) | 61.9 (38.4 to 81.9) | 57.1 (34.0 to 78.2) | 45.5 (24.4 to 67.8) | 40.0 (19.1 to 63.9) | NA (NA to NA) |
Durable SD rate is defined as the percentage of participants whose observed BOR is irSD and the duration of irSD is \>=23 weeks based on irRECIST v1.1.
No measurements were reported for this outcome.
DOR: time from date of first observation of response (irPR or irCR) to date of the first observation of progression based on irRECIST 1.1, or date of death, whatever the cause. irCR: disappearance of all target and non-target lesions. All pathological (whether target or non-target) must have reduction in their short axis \<10 mm. irPR: at least 30% decrease in sum of diameter (SOD) of target lesions, taking as reference baseline sum diameters. irPD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in SOD of target lesions, taking as reference smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
| months | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma |
|---|---|---|---|---|---|---|---|
| Duration of Objective Response (DOR) Based on irRECIST Version 1.1 | NA (8.5 to NA) | 16.6 (9.7 to 18.4) | 12.5 (2.7 to 28.6) | 14.5 (2.4 to NA) | 7.1 (2.2 to 16.8) | 41.0 (4.6 to NA) | — |
Observed plasma concentration of Lenvatinib was reported here quantified by liquid chromatography with tandem mass spectrometry (LCMS/MS) method.
| microgram per liter (mcg/L) | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC |
|---|---|---|
| Cycle 1 Day 1: 0.5-4 hour | 102.5 ± 136.44 | 198.0 ± NA |
| Cycle 1 Day 1: 6-10 hour | 210.5 ± 65.76 | — |
| Cycle 1 Day 15: Predose | 53.9 ± NA | 1.8 ± NA |
| Cycle 1 Day 15: 0.5-4 hour | 78.4 ± NA | 2.6 ± NA |
| Cycle 1 Day 15: 6-10 hour | 366.0 ± NA | 424.0 ± NA |
| Cycle 2 Day 1: Predose | 35.4 ± 13.08 | 364.0 ± NA |
| Cycle 2 Day 1: 2-12 hour | 491.0 ± 247.49 | 374.0 ± NA |
| Cycle 3 Day 1: Predose | 23.3 ± 31.92 | 118.0 ± NA |
| Cycle 4 Day 1: Predose | 28.0 ± 13.93 | 176.0 ± NA |
| Cycle 5 Day 1: Predose | 19.9 ± 14.91 | 2.5 ± NA |
| Cycle 6 Day 1: Predose | 44.4 ± 42.64 | 210.0 ± NA |
Observed plasma concentration of Lenvatinib was reported here quantified by LCMS/MS method.
| mcg/L | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma |
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1:0.5-4 hour | 82.2 ± 145.44 | 35.5 ± 78.13 | 24.0 ± 33.59 | 79.9 ± 118.94 | 41.8 ± 100.34 | 123.8 ± 169.05 | — |
| Cycle 1 Day 1:6-10 hour | 231.7 ± 109.67 | 190.8 ± 96.25 | 154.3 ± 69.56 | 224.1 ± 109.95 | 169.7 ± 95.78 | 214.2 ± 86.51 | 116 ± NA |
| Cycle 1 Day 15:Predose | 66.6 ± 36.56 | 67.2 ± 80.70 | 52.1 ± 61.70 | 62.9 ± 87.36 | 60.9 ± 46.38 | 61.1 ± 69.54 | 52.2 ± NA |
| Cycle 1 Day 15:0.5-4 hour | 129.3 ± 109.72 | 122.4 ± 114.62 | 93.1 ± 117.35 | 275.3 ± 305.30 | 142.8 ± 149.90 | 153.9 ± 135.79 | 45.9 ± NA |
| Cycle 1 Day 15:6-10 hour | 271.3 ± 103.60 | 206.3 ± 97.29 | 241.8 ± 241.52 | 266.8 ± 146.41 | 210.6 ± 78.37 | 249.7 ± 91.65 | 161 ± NA |
| Cycle 2 Day 1:Predose | 57.2 ± 60.58 | 54.6 ± 64.43 | 49.2 ± 46.63 | 51.6 ± 66.72 | 42.0 ± 48.16 | 22.3 ± 21.61 | 26.1 ± NA |
| Cycle 2 Day 1:2-12 hour | 199.7 ± 155.08 | 171.7 ± 119.34 | 218.6 ± 83.83 | 295.0 ± 190.80 | 166.5 ± 128.95 | 204.7 ± 174.60 | — |
| Cycle 3 Day 1:Predose | 53.2 ± 59.53 | 59.0 ± 67.58 | 62.8 ± 65.77 | 99.4 ± 132.33 | 43.7 ± 50.45 | 37.9 ± 29.19 | — |
| Cycle 4 Day 1:Predose | 50.7 ± 52.16 | 56.0 ± 61.56 | 65.8 ± 115.31 | 53.4 ± 81.66 | 34.3 ± 54.94 | 18.8 ± 34.33 | 61.9 ± NA |
| Cycle 5 Day 1:Predose | 53.5 ± 56.69 | 52.1 ± 65.15 | 60.8 ± 58.38 | 71.8 ± 134.39 | 37.7 ± 42.97 | 39.0 ± 29.50 | — |
| Cycle 6 Day 1:Predose | 40.6 ± 33.66 | 51.8 ± 49.19 | 114.0 ± 189.97 | 49.9 ± 68.97 | 36.9 ± 34.12 | 34.2 ± 31.86 | — |
Collected over From date of first dose of the study drugs up to 30 days after the last dose (up to 74 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) |
| Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | 88/124 (71%) | 73/124 (58.9%) | 122/124 (98.4%) |
| Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | 74/145 (51%) | 81/145 (55.9%) | 145/145 (100%) |
| Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | 15/21 (71.4%) | 12/21 (57.1%) | 21/21 (100%) |
| Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | 16/21 (76.2%) | 15/21 (71.4%) | 21/21 (100%) |
| Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | 15/22 (68.2%) | 12/22 (54.5%) | 22/22 (100%) |
| Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | 16/20 (80%) | 17/20 (85%) | 20/20 (100%) |
| Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Event | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma |
|---|---|---|---|---|---|---|---|---|---|
| EncephalopathyNervous system disorders | 0/2 | 1/1 | 3/124 | 1/145 | 0/21 | 0/21 | 0/22 | 0/20 | 0/1 |
| Clostridial sepsisInfections and infestations | 1/2 | 0/1 | 0/124 | 0/145 | 0/21 | 0/21 | 0/22 | 0/20 | 0/1 |
| SepsisInfections and infestations | 0/2 | 0/1 | 1/124 | 3/145 | 0/21 | 0/21 | 0/22 | 3/20 | 0/1 |
| AstheniaGeneral disorders | 0/2 | 0/1 | 2/124 | 1/145 | 1/21 | 0/21 | 0/22 | 2/20 | 0/1 |
| PneumoniaInfections and infestations | 0/2 | 0/1 | 1/124 | 6/145 | 0/21 | 1/21 | 1/22 | 2/20 | 0/1 |
| Acute kidney injuryRenal and urinary disorders | 0/2 | 0/1 | 1/124 | 6/145 | 0/21 | 0/21 | 1/22 | 2/20 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 0/2 | 0/1 | 2/124 | 3/145 | 0/21 | 2/21 | 0/22 | 0/20 | 0/1 |
| CholecystitisHepatobiliary disorders | 0/2 | 0/1 | 0/124 | 3/145 | 2/21 | 0/21 | 0/22 | 0/20 | 0/1 |
| SeizureNervous system disorders | 0/2 | 0/1 | 1/124 | 0/145 | 2/21 | 0/21 | 0/22 | 0/20 | 0/1 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/2 | 0/1 | 0/124 | 0/145 | 0/21 | 2/21 | 1/22 | 0/20 | 0/1 |
| Event | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma |
|---|---|---|---|---|---|---|---|---|---|
| HypothyroidismEndocrine disorders | 1/2 | 1/1 | 61/124 | 60/145 | 7/21 | 8/21 | 6/22 | 8/20 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 2/2 | 1/1 | 79/124 | 97/145 | 13/21 | 12/21 | 8/22 | 11/20 | 0/1 |
| DyspepsiaGastrointestinal disorders | 0/2 | 1/1 | 12/124 | 21/145 | 3/21 | 1/21 | 0/22 | 2/20 | 0/1 |
| NauseaGastrointestinal disorders | 2/2 | 0/1 | 66/124 | 74/145 | 13/21 | 10/21 | 9/22 | 12/20 | 0/1 |
| StomatitisGastrointestinal disorders | 2/2 | 1/1 | 45/124 | 63/145 | 1/21 | 5/21 | 7/22 | 2/20 | 1/1 |
| VomitingGastrointestinal disorders | 1/2 | 0/1 | 56/124 | 44/145 | 9/21 | 8/21 | 6/22 | 10/20 | 1/1 |
| FatigueGeneral disorders | 2/2 | 1/1 | 66/124 | 95/145 | 14/21 | 15/21 | 11/22 | 12/20 | 1/1 |
| Skin infectionInfections and infestations | 2/2 | 0/1 | 0/124 | 0/145 | 0/21 | 0/21 | 0/22 | 0/20 | 0/1 |
| Urinary tract infectionInfections and infestations | 0/2 | 1/1 | 37/124 | 8/145 | 6/21 | 3/21 | 2/22 | 9/20 | 0/1 |
| Decreased appetiteMetabolism and nutrition disorders | 2/2 | 1/1 | 68/124 | 70/145 | 10/21 | 16/21 | 10/22 | 10/20 | 0/1 |
The safety analysis set included all participants who received at least one dose of study drug.
| Age, Customized(Participants) | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| <65 years | 0 | 0 | 47 | 88 | 16 | 9 | 9 | 4 | 1 | 174 |
| >=65 years | 2 | 1 | 77 | 57 | 5 | 12 | 13 | 16 | 0 | 183 |
| Sex: Female, Male(Participants) | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 1 | 124 | 32 | 4 | 10 | 4 | 6 | 1 | 182 |
| Male | 2 | 0 | 0 | 113 | 17 | 11 | 18 | 14 | 0 | 175 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 3 | 17 | 2 | 0 | 1 | 2 | 0 | 26 |
| Not Hispanic or Latino | 1 | 1 | 121 | 128 | 19 | 21 | 21 | 18 | 1 | 331 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC | Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC | Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC | Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC | Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 5 | 3 | 0 | 0 | 0 | 0 | 0 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 7 | 6 | 0 | 3 | 2 | 0 | 1 | 19 |
| White | 2 | 1 | 108 | 125 | 19 | 18 | 20 | 19 | 0 | 312 |
| More than one race | 0 | 0 | 2 | 8 | 1 | 0 | 0 | 1 | 0 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2015 to primary completion in Aug 2020, 60 months.
Results were first posted in Jul 2023, 2 years 11 months after primary completion. A results delay was requested in Jun 2021.
Of 194 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 60 months is close to that.
Counting every sponsor, half of 296 studies reached it within 60 months; a quarter within 39 and three quarters within 89.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib